MAPT and chronic kidney disease: Similarly, clinical studies in patients with chronic kidney disease (CKD) and cognitive dysfunction reported that abnormally elevated levels of Aβ, GSK3-β and tau-p, among others, were reestablished after treatment with rhEPO (100 IU/kg) administered twice weekly for 6 months [134].